Dr. Qiu-Yan Chen is an associate chief physician of Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center. Dr.Chen obtained her Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2009, respectively. She has been engaged in clinical diagnosis and treatment of nasopharyngeal carcinoma since 2000 and she participated several prospective randomized controlled clinical trials.
From 2007 November to 2008 November, she participated in the joint doctoral training project to American University of Pittsburgh for one year by the China Scholarship Council funded. She has chaired one national youth fund and one Guangdong Province Science and technology projects, participated in four National Natural Science Foundations. Dr. Chen has published more than 30 research papers. Nasopharyngeal carcinoma therapy (radiotherapy, chemotherapy, targeted therapy)in clinical work and research.

Sep/1995-Jul/2000  Bachelor in Medicine (equivalent to M.D. in the US)

Sun Yat-sen University of Medical Sciences,Guangzhou, P. R. China

Sep/2004-Sep/2006  Master of Medical Science in Oncology

Sun Yat-sen University ofMedical Sciences, Guangzhou, P. R. China

Sep/2006-Sep/2009 　Ph. D of Medical Science in Oncology

Sun Yat-sen University ofMedical Sciences, Guangzhou, P. R. China

 

1. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH,Sun R, DengMQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, and Mai HQ. Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage IINasopharyngeal Carcinoma: Phase III Randomized Trial. Journal of the National CancerInstitute. 2011;December 7,103(23),1761－70. （IF14.6）
2. Chen QY, Tang QN, Tang LQ, Chen WH, Guo SS, Liu LT, Li CF, Li Y, Liang YJ, Sun XS, Guo L, Mo HY, Sun R, Luo DH, Fan YY, He Y, Chen MY, Cao KJ, Qian CN, Guo X, Mai HQ.Pretreatment Serum Amyloid A and C - Reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study. Cancer Res Treat. 2017 Jul 14. doi: 10.4143/crt.2017.180. [Epub ahead of print] （IF3.772）
3. Chen QY，Qin SY，Liu Y，Hong MH，Qian CN，Keller ET.，Zhang J，Lu Y，IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker，Oncotarget，2016.10.18，7（42）：68140~68150（IF5.168）
4. Tang LQ, Chen QY,（co-author），Fan W, Liu H, Zhang L, GuoL, Luo DH, Huang PY, Zhang X, Lin XP, Mo YX, Liu LZ, Mo HY, Li J, Zou RH, CaoY, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, CaoKJ, Qian CN, Zeng MS, Mai HQ. Prospective study of tailoring whole-bodydual-modality [18F]fluorodeoxyglucose positron emission tomography/computedtomography with plasma Epstein-Barr virus DNA for detecting distant metastasisin endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol.2013 Aug10;31(23):2861-9.（IF 18.038）
5. Li J, Chen QY, （co-author）He J, Li ZL, Tang XF, Chen SP, Xie CM, Li YQ, Huang LX, Ye SB, Ke M, Tang LQ, Liu H, Zhang L, Guo SS, Xia JC, Zhang XS, Zheng LM, Guo X, Qian CN, Mai HQ, Zeng YX. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015 Mar 6;4(2):e976507. eCollection 2015 Feb. （IF 7.719）
6. Liu LT, Chen QY, （co-author）Tang LQ, Zhang L, Guo SS, Xie CM, Liu XW, Guo L, Mo HY, Chen MY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival. Radiology. 2017 Jan;282(1):171-181. doi: 10.1148/radiol.2016152540. Epub 2016 Aug 1. （IF 7.296）
7. Tang LQ, Chen QY, （co-author） Guo SS, Chen WH, Li CF, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Liu H, Liu LT, Yan SM, Guo L, Zhao C, Cao KJ, Liu Q, Qian CN, Ma J, Guo X, Zeng MS, Mai HQ. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer. 2014 Sep 9;111(6):1102-11. doi: 10.1038/bjc.2014.393. Epub 2014 Jul 22. （IF 6.176）
8. Luo DH, Chen QY,（co-author），Liu H, Xu LH,Zhang HZ, Zhang L, Tang LQ, Mo HY, Huang PY, Guo X, Mai HQ.The independent,unfavorable prognostic factors endothelin A receptor and chemokine receptor 4have a close relationship in promoting the motility of nasopharyngeal carcinomacells via the activation of AKT and MAPK pathways. J Transl Med. 2013 Aug29;11(1):203.（IF 3.46）
9. Li J，Chen QY，（co-author），Mo HY, Zhang YL,Huang ZF, Zeng YX. Immunophenotyping at the Time of Diagnosis Distinguishes TwoGroups of Nasopharyngeal Carcinoma Patients: Implications for AdoptiveImmuno-therapy. International Journal of Biological Science, 2011; 7(5):607-617. （IF 3.2）
10. Liu H, Chen QY, （co-author），Guo L, Tang LQ,Mo HY, Zhong ZL, Huang PY, Luo DH, Sun R, Guo X, Cao KJ, Hong MH, Mai HQ.Feasibility and efficacy of chemoradiotherapy for elderly patients withlocoregionally advanced nasopharyngeal carcinoma: results from a matched cohortanalysis. Radiat Oncol. 2013 Mar 22;8(1):70. （IF 2.11）
11. Cai Z, Chen QY, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q. Monocyte chemotactic protein 1 promotes lungcancer–induced bone resorptive lesions in vivo. Neoplasia, 2009，11(3): 228-236.（IF5.4）
12. Lu Y, Chen QY, Corey E, Xie W, Fan J, MizokamiA. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clinical& Experimental Metastasis, 2009,26(2):161-169.（IF4.1）
13. Zhang L, Chen QY, Liu H, Tang LQ, Mai Hq.Emerging treatment options for nasopharyngeal carcinoma. DrugDes Devel Ther. 2013; 7:37-52. （IF 3.486）
14. Lu Y, Nie D, Witt WT, Chen QY, Shen M, Xie H, Lai L, Dai Y. Expression of the fat-1 gene diminishes prostate cancer growth in vivothrough enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. MolecularCancer Therapeutics, 2008，7(10):3202-3211.（IF5.2）
15. Wen YF, Qi B, Liu H, Mo HY, Chen QY, Li J, Huang PY, Ye YF, Zhang Y, Deng MQ, Guo X, Hong MH, Cao KJ, Mai HQ. Polymorphisms in the Endothelin-1 andEndothelin A Receptor Genes and Survival in Patients with LocoregionallyAdvanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2011;17(8):2451-2458. （IF 7.3）
16. He J, Tang XF, ChenQY, Mai HQ, Huang ZF, Li J, Zeng YX. Ex vivo expansion oftumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients foradoptive immunotherapy. Chin J Cancer, 2012， Jan 17. doi:10.5732/cjc.011.10376. [Epub ahead of print]
17. Chen MY, Wang SL, Zhu YL, Shen GP, Qiu F, Luo DH, Chen QY, Jiang R, Cao KJ, QianCN, Hong MH. Use of a posterior pedicle nasal septum and floor mucoperiosteumflap to resurface the nasopharynx after endoscopic nasopharyngectomy forrecurrent nasopharyngeal carcinoma. Head Neck, 2011， Dec 5. doi:10.1002/hed.21928. [Epub ahead of print]
18. Li J,Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ, ChenQY, He J, Chen SP, Zheng LM, Qian CN, Zeng YX. Distribution,characterization, and induction of CD8⁺ regulatory Tcells and IL-17-producing CD8⁺ T cells innasopharyngeal carcinoma. J Transl Med, 2011, Nov 4，9:189.
19. Lv X, Xiang YQ, Cao SM, Qian CN, Li NW, Guo L, Mai HQ, Chen QY, Huang PY, Luo D, CaoKJ, Hong MH, Guo X. Prospective validation of the prognostic value of elevatedserum vascular endothelial growth factor in patients with nasopharyngealcarcinoma: more distant metastases and shorter overall survival aftertreatment. Head Neck, 2011, 33(6):780-5.
20. Cao SM, Yu JK, ChenQY, Li NW, Xiang YQ, Qian CN, Hu X, Zhang CQ, Xie D, Guo X. Detection ofnasopharyngeal carcinoma using surface-enhanced laser desorption and ionizationmass spectrometry profiles of the serum proteome. Chin J Cancer, 2010,29(8):721-8.
21. Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D,Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS.Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transitionand increases the number of side population stem-like cancer cells innasopharyngeal carcinoma. PLoS Pathog, 2010, 6(6):e1000940.
22. Lu X, Guo X, Hong MH, ChenQY, Zeng Q, Xiang YQ. Comparison of the short-term efficacy of twoinductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma:docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin. ChinJ Cancer, 2010, 29(2):140-4.
23. Guo L, Lin HX, Xu M, ChenQY, Wang CT, Huang PY. Phase I study of TPF neoadjuvant chemotherapyfollowed by radical radiotherapy in advanced nasopharyngeal carcinoma. ChinJ Cancer, 2010, 29(2):136-9.
24. Li J, Zhang XS, Xie D, Deng HX, Gao YF, Chen QY, Huang WL, Masucci MG, Zeng YX. Expression ofimmune-related molecules in primary EBV-positive Chinese nasopharyngealcarcinoma: associated with latent membrane protein 1 (LMP1) expression. CancerBiol Ther, 2007, 6(12):1997-2004.

25. Li J, Zeng XH, Mo HY, Rolén U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, LiMZ, Huang WL, Wang XN, Zeng YX, Masucci MG. Functional inactivation ofEBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumorimmunotherapy. PLoS One, 2007, 2(11):e1122.

Updated by International Office, Sun Yat-sen University Cancer Center